Zelluna ASA [ZLNA]: Key information regarding reverse share split and change of ISIN

27 Mar 2025 15:27 CET

Oslo, Norway, 27 March, 2025

Reference is made to the stock exchange notice published on 9 January 2025
regarding an extraordinary general meeting held in Zelluna ASA (the "Company"),
where it was resolved to carry out a reverse share split in the ratio 10:1.

Radforsk Investeringsstiftelse has further agreed with the Company to make
available, without any compensation a, necessary number of its existing shares
to the Company to ensure that all fractions of shares are rounded up to the
nearest whole share, thus avoiding that shareholders will have its shareholdings
rounded off downwards.

Please note the following key information in relation to the reverse share
split:
- Date on which the corporate action was made public: 19 December 2024 (notice
of extraordinary general meeting)
- Date of approval: 9 January 2025 (extraordinary general meeting held)
- Reverse split ratio: Ten (10) old shares give one (1) new share
- Last day including right: 31 March 2025
- Ex-date: 1 April 2025
- Record date: 2 April 2025

In connection with the reverse share split, the Company's shares will be
transferred to a new ISIN. Please note the following key information for the
change of ISIN:
- Issuer: Zelluna ASA
- Previous ISIN: NO 001 0851603
- New ISIN: NO 001 3524942
- Date of ISIN change: 1 April 2025

For further information, please contact:

Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com (mailto:[%20hans.eid@zelluna.com])
Phone: +47 482 48632

About Zelluna ASA
Zelluna's mission is to deliver transformative treatments with the capacity to
cure advanced solid cancers, in a safe and cost-efficient manner, to patients on
a global scale. The Company aims to do this by combining the most powerful
elements of the immune system through pioneering the development of "off the
shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK).
The TCR-NK platform offers a unique mechanism of action with broad cancer
detection capability to overcome the diversity of tumours and will be used "off
the shelf" to overcome scaling limitations of current cell therapies. The lead
program is a world's first MAGE-A4 targeting "off the shelf" TCR-NK for the
treatment of various solid cancers; a pipeline of earlier products follows. The
Company is led by a management team of biotech entrepreneurs with deep
experience in discovery through to clinical development of TCR and cell-based
therapies including marketed products.

More information:
Access the news on Oslo Bors NewsWeb site